Canaccord Genuity Releases a Buy Rating on Karyopharm Therapeutics

By Austin Angelo

In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $20. The company’s shares opened today at $10.39.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 7.3% and a 47.7% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Karyopharm Therapeutics is Moderate Buy and the average price target is $21, representing a 102.1% upside.

In a report released today, JMP Securities also maintained a Buy rating on the stock with a $22 price target.

The company has a one year high of $14.63 and a one year low of $6.27. Currently, Karyopharm Therapeutics has an average volume of 227.9K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KPTI in relation to earlier this year. Most recently, in November 2016, Ran Frenkel, the Chief Dev Operations Officer of KPTI sold 3,309 shares for a total of $33,255.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.